Carlson Capital’s Bristol-Myers Squibb BMY Stock Holding History

Carlson Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,983	Closed	-$901K	–	259
2019 Q1	$901K	Buy	+13,983	New	+$697K	0.02%	233

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carlson Capital's BMY Position: Q3 2024 in Review

Carlson Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 42,500 shares — an estimated $1.77M sold.

Carlson Capital first reported a position in BMY in Q2 2015 and held it in 4 quarters. The position peaked at $17.5M in Q2 2015. 2,263 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Carlson Capital reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Carlson Capital sold 42,500 Bristol-Myers Squibb shares in Q3 2024, an estimated $1.77M.
Carlson Capital first reported a position in Bristol-Myers Squibb in Q2 2015 and held it in 4 quarters.
Carlson Capital's Bristol-Myers Squibb position peaked at $17.5M in Q2 2015.
2,263 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Carlson Capital's 13F filing for Q3 2024, filed 14 Nov 2024.